In September, I discussed new anticoagulants Xarelto and Eliquis. My prior post concludes by noting patients deserve drugs approved only after careful study for safety.

Shortly after that post, the ISMP Quarterwatch also raised issues concerning the safety of new anticoagulants rivaroxaban (Xarelto), dabigatron (Pradaxa), and apixaban (Eliquis). According to Quarterwatch:

The adverse event

Will Eliquis join Pradaxa and Xarelto as another anti-coagulant drug facing claims of severe internal bleeding? Pradaxa was the first of these three new anti-coagulants (blood thinners). It hit the market in 2010. Sales quickly boomed. However, adverse reports of severe internal hemorrhaging and bleeding soon followed. In May 2014, Pradaxa’s manufacturer settled about 4,000

What is Xarelto?

Xarelto (Rivaroxaban) is a relatively new anticoagulant (blood thinner). The FDA first approved Xarelto in 2011. It is distributed in the United States by Johnson & Johnson subsidiary Janssen Pharmaceuticals and Bayer Healthcare. Xarelto was released as a replacement for Coumadin (Warfarin), a blood thinner effectively used for decades.

Xarelto is used

We are presently representing clients who have been injured by several different defective medical products, including the diabetes drug Actos and transvaginal mesh. As part of our work, we have studied much of the available medical research.

Recently, I viewed an interesting discussion on an issue important in the medical research. The issue is:

Recent decisions from the U.S. Supreme Court have allowed generic drug manufacturers to escape justice for the personal injuries and deaths caused by their dangerous and defective products. It is unjust that any company could market a defective product and not be accountable for the harm it causes. Yet, our law now provides generic drug manufacturers